Michael Pourdehnad
0000-0001-8701-930X
48 papers found
Refreshing results…
Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)
A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC.
CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity
A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001
A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma
CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines
CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models
Atim-28. A Phase 1a/1b, Multi-Center, Open-Label Dose Finding Study to Assess the Safety, Tolerability and Efficacy of the Pleiotropic Pathway Modifier Cc-122 Administered Orally to Patients With Glioblastoma Multiforme (Gbm) and Other Brain Tumors
CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity
CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma
CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse
CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways
CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma
CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide
Abstract A46: Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Investigating Myc-Dependent Translational Regulation in Normal and Cancer Cells
Stability of cerebral blood flow measures using a split-dose technique with 99mTc-exametazime SPECT:
Missing publications? Search for publications with a matching author name.